Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
作者信息
Schwarzschild Michael A
出版信息
J Parkinsons Dis. 2017;7(1):79-80. doi: 10.3233/JPD-160975.
Abstract
摘要
相似文献
1
Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?是单胺氧化酶B抑制剂撤药而非尼罗替尼的作用能解释帕金森病研究对象中多巴胺代谢物的增加吗？
J Parkinsons Dis. 2017;7(1):79-80. doi: 10.3233/JPD-160975.
2
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.（-）-司来吉兰，一种选择性单胺氧化酶-B抑制剂，具有促凋亡和抗凋亡特性。
Neurotoxicology. 2004 Jan;25(1-2):233-42. doi: 10.1016/S0161-813X(03)00102-5.
3
A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties.一种具有神经保护和抗帕金森病特性的新型选择性 MAO-B 抑制剂。
Eur J Pharmacol. 2018 Jan 5;818:254-262. doi: 10.1016/j.ejphar.2017.10.023. Epub 2017 Oct 17.
4
Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms.血小板单胺氧化酶、戒烟与烟草戒断症状
Nicotine Tob Res. 2001 Nov;3(4):383-90. doi: 10.1080/14622200110087277.
5
Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.选择性抑制单胺氧化酶 A 或 B 可降低黑质纹状体多巴胺能通路部分耗竭大鼠纹状体的氧化应激。
Neuropharmacology. 2013 Feb;65:48-57. doi: 10.1016/j.neuropharm.2012.08.023. Epub 2012 Sep 7.
6
Modification of L-DOPA pharmacological activity by MAO inhibitors.单胺氧化酶抑制剂对左旋多巴药理活性的修饰作用。
J Neural Transm (Vienna). 2007;114(6):801-5. doi: 10.1007/s00702-007-0691-y. Epub 2007 Apr 10.
7
Effect of scopoletin on monoamine oxidases and brain amines.
Neurochem Int. 2016 Feb;93:113-7. doi: 10.1016/j.neuint.2016.01.001. Epub 2016 Jan 19.
8
Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels.高剂量司来吉兰重复治疗对行为、纹状体多巴胺能传递及酪氨酸羟化酶mRNA水平的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):22-8. doi: 10.1007/s00210-001-0492-z. Epub 2001 Nov 8.
9
Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.新型单胺氧化酶-B抑制剂PF9601N的神经保护作用
Neurobiology (Bp). 2000;8(3-4):231-6.
10
Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.1-甲基-4-苯基-1,2,3,6-四氢吡啶对A 型和B 型单胺氧化酶的抑制作用
J Pharmacol Exp Ther. 1985 Mar;232(3):696-701.
引用本文的文献
1
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson's Disease.用于帕金森病疾病修饰作用的药物重新定位与再利用
J Mov Disord. 2025 Apr;18(2):113-126. doi: 10.14802/jmd.25008. Epub 2025 Feb 7.
2
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.帕金森病的疾病修饰治疗方法：临床试验及经验教训。
Neurotherapeutics. 2020 Oct;17(4):1393-1405. doi: 10.1007/s13311-020-00964-w. Epub 2020 Nov 17.
3
Recent developments in the treatment of Parkinson's Disease.帕金森病治疗的最新进展。
F1000Res. 2020 Jul 31;9. doi: 10.12688/f1000research.25634.1. eCollection 2020.
本文引用的文献
1
Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.尼洛替尼在帕金森病和路易体痴呆中的作用。
J Parkinsons Dis. 2016 Jul 11;6(3):503-17. doi: 10.3233/JPD-160867.
2
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.帕金森病 DATATOP 研究中的脑脊液高香草酸。帕金森研究小组。
Arch Neurol. 1995 Mar;52(3):237-45. doi: 10.1001/archneur.1995.00540270025015.
3
Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.左旋丙炔苯丙胺（司来吉兰）停药后人类大脑单胺氧化酶B恢复缓慢。
Synapse. 1994 Oct;18(2):86-93. doi: 10.1002/syn.890180203.
4
Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.司来吉兰对阿尔茨海默病患者脑脊液单胺代谢产物的剂量依赖性效应。
Psychopharmacology (Berl). 1987;91(3):293-6. doi: 10.1007/BF00518180.
5
Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.
J Neural Transm Park Dis Dement Sect. 1991;3(1):15-25. doi: 10.1007/BF02251133.
Zotero 插件